

47. (NEW) An antibody directed against HIV-1 p18 antigen, wherein said antibody is formed using an HIV-1 extract containing p18.

48. (NEW) An antibody directed against HIV-1 p18 antigen, wherein said antibody is formed using purified HIV-1 p18 protein.

49. (NEW) The antibody of any one of claims 45-48, wherein said antibody is monoclonal.--

**REMARKS**

Reconsideration of this application is respectfully requested. Applicants have canceled claims 37, 38, and 41-44. New claims 45-49 are derived from canceled claims 37, 38, and 42, and are fully supported by the specification, for example, as follows:

<b><u>Claim</u></b>	<b><u>Support</u></b>
45-48	Page 4, lines 1-10; page 13, lines 11-13; page 14, lines 15-26; page 15, lines 23-25; and page 30, line 24, through page 31, line 3.
49	Page 30, line 24, through page 31, line 3.

Applicants thank Examiner Parkin and Examiner Housel for the courtesy of the Interview held on April 11, 2002, in which applicants were informed that the basis for the rejection under 35 U.S.C. § 112, first paragraph, was due to the lack of a working example of making antibodies against the claimed HIV-1 proteins. The Office indicated that a working example was required to show possession of applicants' claimed antibodies.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com